AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19092935 — intervention group
Group type: EXPERIMENTAL
Intervention: CIEF educational programs (n=23 PCPs)
Number of subjects: 120
Study 19092935 — intervention group
Group type: EXPERIMENTAL
Intervention: CIEF educational programs (PCPs)
Number of subjects: 120
Study 19092935 — intervention group
Group type: EXPERIMENTAL
Intervention: CIEF educational programs
Number of subjects: 120
Study 19092935 — intervention group
Group type: COMPARATOR
Intervention: Non-CIEF educational programs
Number of subjects: 120
Study 19092935 — intervention group
Group type: COMPARATOR
Intervention: UROs
Number of subjects: 120
Study 17166304 — intervention group
Group type: EXPERIMENTAL
Intervention: Working Memory (WM) and Inhibitory Control (IC)
Number of subjects: 96
Study 12854145 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic total mesorectal excision (LTME) with preservation of anal sphincter
Number of subjects: 82
Study 12854145 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic low anterior resection (LLAR)
Number of subjects: 82
Study 12854145 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic ultralow anterior resection (LULAR)
Number of subjects: 82
Study 12854145 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic coloanal anastomoses (LCAA)
Number of subjects: 82
Study 12854145 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative recovery
Number of subjects: 82
Study 12854145 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean operating time
Number of subjects: 82
Study 12854145 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean operative blood loss
Number of subjects: 82
Study 12854145 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean hospital stay
Number of subjects: 82
Study 12854145 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative complications
Number of subjects: 82
Study 12854145 — intervention group
Group type: EXPERIMENTAL
Intervention: Interoperative complications
Number of subjects: 82
Study 11195876 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual lymph drainage (10 treatments)
Number of subjects: 26
Study 11195876 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional treatment with exercises, movement, oedema control, and education)
Number of subjects: 26
Study 9316510 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg/day)
Number of subjects: 695
Study 9316510 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 695
Study 8402758 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase
Number of subjects: 150
Study 8402758 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase
Number of subjects: 150
Study 3780825 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral high-dose metoclopramide
Number of subjects: 12
Study 3780825 — intervention group
Group type: COMPARATOR
Intervention: Intravenous metoclopramide
Number of subjects: 12
Study 29972535 — intervention group
Group type: EXPERIMENTAL
Intervention: Ear protectors
Number of subjects: 12
Study 29972535 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ear protectors)
Number of subjects: 12
Study 29931843 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligustrazine hydrochloride injection (LHI)
Number of subjects: 22
Study 29931843 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (group C)
Number of subjects: 22
Study 29931843 — intervention group
Group type: COMPARATOR
Intervention: Normal control group (group N)
Number of subjects: 22
Study 24807158 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (4 courses intravenous carboplatin day 1 and oral vinorelbine day 1 and 8, at 3‐week intervals)
Number of subjects: 188
Study 24807158 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus radiotherapy (CRT) (radiotherapy with fractionation 42 Gy/15 starting at the second chemotherapy course)
Number of subjects: 188
Study 24807158 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus radiotherapy (CRT)
Number of subjects: 188
Study 24807158 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (without CRT)
Number of subjects: 188
Study 22452559 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-mg nasal nicotine spray (0.5 mg each nostril)
Number of subjects: 19
Study 22452559 — intervention group
Group type: COMPARATOR
Intervention: Placebo (pepper) spray
Number of subjects: 19
Study 19695854 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin/Fluvastatin treatment for 16 weeks
Number of subjects: 20
Study 18681363 — intervention group
Group type: EXPERIMENTAL
Intervention: IUI with COH
Number of subjects: 253
Study 18681363 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 253
Study 15955040 — intervention group
Group type: EXPERIMENTAL
Intervention: Epilepsy patients with migraine (EM group)
Number of subjects: 115
Study 15955040 — intervention group
Group type: COMPARATOR
Intervention: Epilepsy patients without migraine (E group)
Number of subjects: 115
Study 12600905 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (136 IU) plus slow-release vitamin C (250 mg) twice daily
Number of subjects: 520
Study 10536636 — intervention group
Group type: EXPERIMENTAL
Intervention: Binary content checklist
Number of subjects: 42
Study 10536636 — intervention group
Group type: EXPERIMENTAL
Intervention: Global process rating
Number of subjects: 42
Study 10536636 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized patient interviews
Number of subjects: 42
Study 9102014 — intervention group
Group type: EXPERIMENTAL
Intervention: Minilaparotomy (ML)
Number of subjects: 0
Study 9102014 — intervention group
Group type: COMPARATOR
Intervention: Conventional transabdominal approach (CTA)
Number of subjects: 0
Study 1856405 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure group
Number of subjects: 284
Study 1856405 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 284
Study 1856405 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure group with three-vessel coronary artery disease
Number of subjects: 284
Study 1856405 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure group without coronary artery disease
Number of subjects: 284
Study 1856405 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure group who underwent surgical revascularization
Number of subjects: 284
Study 6406886 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal educational visits by clinical pharmacists and mailed 'unadvertisements'
Number of subjects: 435
Study 6406886 — intervention group
Group type: COMPARATOR
Intervention: Mailed print materials only
Number of subjects: 435
Study 30850024 — intervention group
Group type: EXPERIMENTAL
Intervention: PBL assessment rating scale of 12 different criteria on a six-point scale
Number of subjects: 181
Study 28274210 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation (PR) starting within 4 weeks after randomization (Intervention Group, IG)
Number of subjects: 0
Study 28274210 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control (Control Group, CG) starting PR 20 weeks after randomization
Number of subjects: 0
Study 28274210 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation (PR)
Number of subjects: 0
Study 26641853 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical discectomy
Number of subjects: 1244
Study 26641853 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonoperative care
Number of subjects: 1244
Study 25112923 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients' beliefs regarding symptoms associated with ulceration, understanding of ulceration, and perceived personal control over ulceration.
Number of subjects: 169
Study 25112923 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline foot self-care behaviours (week 0)
Number of subjects: 169
Study 25112923 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and ulcer size
Number of subjects: 169
Study 25112923 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions aimed at modifying illness beliefs
Number of subjects: 169
Study 22287037 — intervention group
Group type: EXPERIMENTAL
Intervention: FR-aspirin 650 mg
Number of subjects: 0
Study 22287037 — intervention group
Group type: EXPERIMENTAL
Intervention: FR-aspirin 1000 mg
Number of subjects: 0
Study 22287037 — intervention group
Group type: COMPARATOR
Intervention: R-aspirin 650 mg
Number of subjects: 0
Study 22287037 — intervention group
Group type: COMPARATOR
Intervention: R-aspirin 1000 mg
Number of subjects: 0
Study 22287037 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19865059 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of enoxaparin sodium and bed rest (Group B)
Number of subjects: 48
Study 19865059 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of enoxaparin sodium and thigh-length compression stockings (Group C)
Number of subjects: 48
Study 19865059 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of enoxaparin sodium and pneumatic compression (Group D)
Number of subjects: 48
Study 19865059 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous unfractionated heparin (Group A)
Number of subjects: 48
Study 17526857 — intervention group
Group type: EXPERIMENTAL
Intervention: Emtricitabine in combination with stavudine
Number of subjects: 0
Study 17526857 — intervention group
Group type: EXPERIMENTAL
Intervention: Emtricitabine in combination with famciclovir
Number of subjects: 0
Study 17526857 — intervention group
Group type: EXPERIMENTAL
Intervention: Emtricitabine in combination with zidovudine
Number of subjects: 0
Study 17526857 — intervention group
Group type: EXPERIMENTAL
Intervention: Emtricitabine in combination with zidovudine glucuronide
Number of subjects: 0
Study 17526857 — intervention group
Group type: COMPARATOR
Intervention: Emtricitabine alone
Number of subjects: 0
Study 17526857 — intervention group
Group type: COMPARATOR
Intervention: Stavudine alone
Number of subjects: 0
Study 17526857 — intervention group
Group type: COMPARATOR
Intervention: Famciclovir alone
Number of subjects: 0
Study 17526857 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine alone
Number of subjects: 0
Study 17526857 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine glucuronide alone
Number of subjects: 0
Study 14504156 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal tramadol 25 mg
Number of subjects: 64
Study 14504156 — intervention group
Group type: COMPARATOR
Intervention: Saline 0.5 ml
Number of subjects: 64
Study 10476732 — intervention group
Group type: EXPERIMENTAL
Intervention: albendazole
Number of subjects: 448
Study 10476732 — intervention group
Group type: EXPERIMENTAL
Intervention: mebendazole
Number of subjects: 448
Study 10476732 — intervention group
Group type: EXPERIMENTAL
Intervention: further chemotherapy cycles
Number of subjects: 448
Study 10476732 — intervention group
Group type: COMPARATOR
Intervention: control group (not specified)
Number of subjects: 448
Study 8927674 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 41
Study 8927674 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium alone
Number of subjects: 41
Study 8927674 — intervention group
Group type: COMPARATOR
Intervention: Lithium plus neuroleptics
Number of subjects: 41
Study 1798845 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine
Number of subjects: 18
Study 1798845 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 6645218 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional hemodialysis with dialysate sodium concentration 7% below predialysis serum concentration
Number of subjects: 5
Study 6645218 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional hemodialysis with dialysate sodium concentration equal to predialysis serum concentration
Number of subjects: 5
Study 6645218 — intervention group
Group type: EXPERIMENTAL
Intervention: High sodium dialyses with dialysate sodium concentration 7% above predialysis serum concentration
Number of subjects: 5
Study 30942031 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with prednisone
Number of subjects: 48
Study 30942031 — intervention group
Group type: COMPARATOR
Intervention: Simple acupuncture
Number of subjects: 48
Study 28056917 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulranumab 9 mg administered subcutaneously at weeks 1, 5, and 9
Number of subjects: 31
Study 28056917 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered subcutaneously at weeks 1, 5, and 9
Number of subjects: 31
Study 28056917 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulranumab 9 mg
Number of subjects: 31
Study 28056917 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 25001267 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group received a 20 stipend monthly and engaged in social/leisure activities for 2 hours weekly over a 9-month period.
Number of subjects: 107
Study 25001267 — intervention group
Group type: COMPARATOR
Intervention: Control group received a 20 monthly stipend and engaged in a weekly social/leisure activity.
Number of subjects: 107
Study 25001267 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 107
Study 25001267 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 107
Study 23959669 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 22
Study 23959669 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 22
Study 23959669 — intervention group
Group type: COMPARATOR
Intervention: Control (Healthy Volunteers)
Number of subjects: 22
Study 21613452 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula with 8 g/L of a specific prebiotic mixture (short‐chain galacto‐oligosaccharides and long‐chain fructo‐oligosaccharides, ratio 9:1)
Number of subjects: 20
Study 21613452 — intervention group
Group type: COMPARATOR
Intervention: Formula containing the same amount of maltodextrin (placebo)
Number of subjects: 20
Study 19656409 — intervention group
Group type: EXPERIMENTAL
Intervention: Meltdown
Number of subjects: 20
Study 19656409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 16368344 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass grafting (OPCAB)
Number of subjects: 40
Study 16368344 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting with cardiopulmonary bypass (CABG-CPB)
Number of subjects: 40
Study 16219018 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (EX) group (n=15) - supervised exercise twice a week for 12 weeks
Number of subjects: 29
Study 16219018 — intervention group
Group type: COMPARATOR
Intervention: Control (CO) group (n=14)
Number of subjects: 29
Study 16219018 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (EX) group (n=15) - increase in pedometer activity
Number of subjects: 29
Study 10692984 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day
Number of subjects: 129
Study 10692984 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 150 mg/day
Number of subjects: 129
Study 10692984 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day and 150 mg/day
Number of subjects: 129
Study 10692984 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study 8741209 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine (CPZ) 1 mg/kg or 4 mg/kg
Number of subjects: 0
Study 8741209 — intervention group
Group type: EXPERIMENTAL
Intervention: Berberine 200 mg
Number of subjects: 0
Study 8741209 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinic acid 2 g
Number of subjects: 0
Study 8741209 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline (single dose)
Number of subjects: 0
Study 8741209 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 0
Study 8741209 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioflorin
Number of subjects: 0
Study 8741209 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose short-chain polymers with anthracene-9-carboxylic acid (A9C)
Number of subjects: 0
Study 8741209 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandins (PGs)
Number of subjects: 0
Study 1914797 — intervention group
Group type: COMPARATOR
Intervention: Soluble human insulin (Actrapid HM U-100)
Number of subjects: 6
Study 1914797 — intervention group
Group type: EXPERIMENTAL
Intervention: AspB10
Number of subjects: 6
Study 1914797 — intervention group
Group type: EXPERIMENTAL
Intervention: AspB9, GluB27
Number of subjects: 6
Study 1914797 — intervention group
Group type: EXPERIMENTAL
Intervention: AspB28
Number of subjects: 6
Study 7121133 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexiletine (200 mg three times per day)
Number of subjects: 5
Study 7121133 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 7121133 — intervention group
Group type: EXPERIMENTAL
Intervention: Betahistidine
Number of subjects: 5
Study 7121133 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 5
Study 30676224 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated Horseback Riding (SHR) exercises for 30 minutes, 2 days per week for 8 weeks
Number of subjects: 48
Study 30676224 — intervention group
Group type: COMPARATOR
Intervention: Stabilization (STB) exercises for 30 minutes, 2 days per week for 8 weeks
Number of subjects: 48
Study 30676224 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated Horseback Riding (SHR)
Number of subjects: 48
Study 30676224 — intervention group
Group type: COMPARATOR
Intervention: Stabilization (STB)
Number of subjects: 48
Study 31278907 — intervention group
Group type: EXPERIMENTAL
Intervention: HFNC group (O2 [30-60 L/minute] via HFNC)
Number of subjects: 1994
Study 31278907 — intervention group
Group type: COMPARATOR
Intervention: Nasal cannula group (O2 [2 L/minute] via nasal cannula)
Number of subjects: 1994
Study 28424045 — intervention group
Group type: EXPERIMENTAL
Intervention: ModiMedDiet (modified Mediterranean diet)
Number of subjects: 67
Study 28424045 — intervention group
Group type: COMPARATOR
Intervention: Social support control group
Number of subjects: 67
Study 26711786 — intervention group
Group type: EXPERIMENTAL
Intervention: MABC subgroup
Number of subjects: 158
Study 26711786 — intervention group
Group type: EXPERIMENTAL
Intervention: MABC subgroup with positive HSP27 expression
Number of subjects: 158
Study 26711786 — intervention group
Group type: EXPERIMENTAL
Intervention: MABC subgroup with positive GCDFP15 expression
Number of subjects: 158
Study 26711786 — intervention group
Group type: EXPERIMENTAL
Intervention: MABC subgroup with HSP27 and GCDFP15 co-expression
Number of subjects: 158
Study 25359007 — intervention group
Group type: EXPERIMENTAL
Intervention: Habit-formation intervention for child-feeding goals (giving fruit and vegetables, water, healthy snacks) over four fortnightly home visits
Number of subjects: 57
Study 22515513 — intervention group
Group type: EXPERIMENTAL
Intervention: HD203 (25 mg/mL, administered subcutaneously)
Number of subjects: 37
Study 22515513 — intervention group
Group type: COMPARATOR
Intervention: Enbrel® (25 mg/mL, administered subcutaneously)
Number of subjects: 37
Study 20618779 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste containing 1% chlorhexidine used for 14 days
Number of subjects: 0
Study 20618779 — intervention group
Group type: COMPARATOR
Intervention: Dentifrice without chlorhexidine
Number of subjects: 0
Study 18949318 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombocytopenic patients (TCP)
Number of subjects: 86
Study 16212294 — intervention group
Group type: EXPERIMENTAL
Intervention: LASIK surgery
Number of subjects: 5081
Study 11847596 — intervention group
Group type: EXPERIMENTAL
Intervention: Surface-modified CPB circuit (SMA)
Number of subjects: 122
Study 11847596 — intervention group
Group type: COMPARATOR
Intervention: Control group (unmodified CPB circuit)
Number of subjects: 122
Study 10625522 — intervention group
Group type: EXPERIMENTAL
Intervention: SINGLE meal pre-load (served as a single meal)
Number of subjects: 8
Study 10625522 — intervention group
Group type: COMPARATOR
Intervention: MULTI meal pre-load (divided into five equal portions served hourly)
Number of subjects: 8
Study 10625522 — intervention group
Group type: EXPERIMENTAL
Intervention: SINGLE meal pre-load
Number of subjects: 8
Study 10625522 — intervention group
Group type: COMPARATOR
Intervention: MULTI meal pre-load
Number of subjects: 8
Study 8540510 — intervention group
Group type: EXPERIMENTAL
Intervention: OM 20 mg once daily for 4 weeks
Number of subjects: 180
Study 8540510 — intervention group
Group type: EXPERIMENTAL
Intervention: OM 40 mg once daily for 4 weeks
Number of subjects: 180
Study 8540510 — intervention group
Group type: EXPERIMENTAL
Intervention: OM 20 mg daily for 12 months
Number of subjects: 180
Study 8540510 — intervention group
Group type: EXPERIMENTAL
Intervention: OM 20 mg alternate days for 12 months
Number of subjects: 180
Study 8540510 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 180
Study 2023715 — intervention group
Group type: EXPERIMENTAL
Intervention: D15 panel test
Number of subjects: 99
Study 2023715 — intervention group
Group type: EXPERIMENTAL
Intervention: desaturated D15 test
Number of subjects: 99
Study 2023715 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual inspection
Number of subjects: 99
Study 2023715 — intervention group
Group type: EXPERIMENTAL
Intervention: CDV analysis
Number of subjects: 99
Study 2023715 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative scoring techniques
Number of subjects: 99
Study 31839279 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus oseltamivir
Number of subjects: 3266
Study 31839279 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 3266
Study 31227530 — intervention group
Group type: EXPERIMENTAL
Intervention: Double balloon catheter for 12 hours with oxytocin after 6 hours
Number of subjects: 80
Study 31227530 — intervention group
Group type: COMPARATOR
Intervention: Vaginal prostaglandin for 24 hours followed by oxytocin infusion alone
Number of subjects: 80
Study 29212681 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly cross‐linked polyethylene (XLPE)
Number of subjects: 91
Study 29212681 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra‐high molecular weight polyethylene (UHMWPE)
Number of subjects: 91
Study 29212681 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic‐on‐ceramic (CoC)
Number of subjects: 91
Study 29212681 — intervention group
Group type: EXPERIMENTAL
Intervention: All three bearing groups
Number of subjects: 91